USNA — USANA Health Sciences Income Statement
0.000.00%
Last trade - 00:00
- $849.08m
- $519.45m
- $921.01m
- 97
- 79
- 56
- 91
2019 December 28th | 2021 January 2nd | 2022 December 31st | 2022 January 1st | 2023 December 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,061 | 1,135 | 999 | 1,186 | 921 |
Cost of Revenue | |||||
Gross Profit | 873 | 926 | 805 | 969 | 744 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 915 | 958 | 891 | 1,016 | 828 |
Operating Profit | 146 | 176 | 108 | 170 | 93.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 150 | 178 | 109 | 171 | 102 |
Provision for Income Taxes | |||||
Net Income After Taxes | 101 | 125 | 69.3 | 117 | 63.8 |
Net Income Before Extraordinary Items | |||||
Net Income | 101 | 125 | 69.3 | 117 | 63.8 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 101 | 125 | 69.3 | 117 | 63.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 4.41 | 5.86 | 3.59 | 5.73 | 3.3 |